WP
IRON icon

Woodline Partners’s Disc Medicine IRON Stock Holding History

Woodline Partners’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.3M Buy
958,281
+448
+0% +$31.1K 0.23% 104
2025
Q4 		$76.1M Buy
957,833
+90,878
+10% +$7.68M 0.29% 69
2025
Q3 		$57.3M Hold
866,955
– – 0.27% 89
2025
Q2 		$45.9M Buy
866,955
+364,725
+73% +$17.1M 0.24% 112
2025
Q1 		$24.9M Buy
502,230
+105,630
+27% +$5.87M 0.16% 186
2024
Q4 		$25.1M Buy
396,600
+19,538
+5% +$1.13M 0.17% 174
2024
Q3 		$18.5M Buy
377,062
+109,199
+41% +$5.13M 0.16% 204
2024
Q2 		$12.1M Buy
+267,863
New +$9.1M 0.12% 229
2023
Q3 		– Sell
-68,146
Closed -$3.03M – 670
2023
Q2 		$3.03M Buy
+68,146
New +$2.42M 0.04% 372
2021
Q4 		– Sell
-6,266
Closed -$759K – 746
2021
Q3 		$759K Buy
6,266
+4,992
+392% +$682K 0.01% 527
2021
Q2 		$247K Sell
1,274
-10,003
-89% -$3.29M ﹤0.01% 484
2021
Q1 		$4.58M Buy
+11,277
New +$5.03M 0.1% 202

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Woodline Partners's IRON Position: Q1 2026 in Review

Woodline Partners increased its Disc Medicine (IRON) stake by 0.05% in Q1 2026, buying an estimated $31.1K and bringing the position to 958,281 shares worth $61.3M. The position accounts for 0.23% of the portfolio, ranked #104.

Woodline Partners first reported a position in IRON in Q1 2021 and has held it in 12 quarters since. The position peaked at $76.1M in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Woodline Partners held 958,281 shares of Disc Medicine worth $61.3M as of Q1 2026.
  • Woodline Partners bought 448 Disc Medicine shares in Q1 2026, an estimated $31.1K.
  • Disc Medicine made up 0.23% of Woodline Partners's portfolio in Q1 2026, its #104 holding.
  • Woodline Partners first reported a position in Disc Medicine in Q1 2021 and has held it in 12 quarters since.
  • Woodline Partners's Disc Medicine position peaked at $76.1M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.